U.S. Food and Drug Administration Approved 30% More Drugs in 2012 Than the Year Previous

RDInvesting Provides Stocks Research on DARA Biosciences and PDL BioPharma

Marketwired

NEW YORK, NY--(Marketwire - Feb 19, 2013) - A sharp increase in drug approvals and mergers and acquisitions combined to create a bull market for the Biotechnology Industry in 2012. The iShares NASDAQ Biotechnology Index (IBB), the SPDR S&P Biotech ETF (XBI) and the First Trust Amex Biotechnology Index ETF (FBT) have all gained over 20 percent in the past year, outperforming the broader markets by a good margin. Research Driven Investing examines investing opportunities in the Biotech Industry and provides equity research on DARA Biosciences Inc. (NASDAQ: DARA) and PDL BioPharma Inc. (NASDAQ: PDLI).

Access to the full company reports can be found at:

www.RDInvesting.com/DARA

www.RDInvesting.com/PDLI

Bloomberg recently reported drug approvals by the U.S. Food and Drug Administration reached a 15 year high in 2012. The FDA approved a total of 39 novel medicines last year, an increase of 30 percent when compared to a year ago. Oncology drugs lead the way with 11 new drugs approved last year. Over the last ten years the number of FDA approvals had averaged roughly 23 a year. The passage of the Prescription Drug User Fee Act (PDUFA) played a major role in the sharp increase in approvals.

The PDUFA "has provided critical resources for improving the quality and timeliness of premarket review of drugs," said FDA spokeswoman, Sandy Walsh. "These accomplishments could not have been achieved without the innovations of the biopharmaceutical industry and the dedication and skill of FDA's drug review staff."

Research Driven Investing releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and industry newsletters.

DARA has comprehensive commercial coverage across the national oncology market through a series of agreements with a number of specialty pharmacy providers, leading group purchasing organizations, retail partners, reimbursement experts, and an industry-leading third-party logistics provider. DARA's Soltamox is the only oral liquid therapy for breast cancer approved by the FDA and is protected by a US patent until 2018.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. The company's Board of Directors has declared a regular quarterly dividend of $0.15 per share, for a yield of approximately 8.65 percent. Shares of PDL have gained over 10 percent year-to-date.

Research Driven Investing has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

http://www.rdinvesting.com/disclaimer

Rates

View Comments (0)